The U.S. FDA has approved an expanded indication for Sanofi’s Lantus® (insulin glargine) to improve glycemic control in adult and pediatric patients who have diabetes mellitus (type 1 or type 2).

• Prior to this expansion, Lantus was indicated to improve glycemic control in adults who had type 1 or type 2 diabetes mellitus, and in pediatric patients who had type 1 diabetes mellitus.
• Lantus dosing is individualized based on the patient’s metabolic needs, blood glucose monitoring, glycemic control, type of diabetes, and prior insulin use.
• The FDA first approved Lantus in 2000.